Y. Poulin

发表

Olumacostat glasaretil, a novel topical sebum inhibitor, in the treatment of acne vulgaris: A phase IIa, multicenter, randomized, vehicle‐controlled study

H. Hofland, R. Bissonnette, Y. Poulin, 2017, Journal of the American Academy of Dermatology.

Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis.

A. Gottlieb, K. Gordon, S. Tyring, 2007, Archives of dermatology.

Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials

E. H. Thompson, B. Strober, M. Lebwohl, 2018, The Lancet.

Approach to the Management of Patients With Hidradenitis Suppurativa: A Consensus Document

W. Gulliver, M. Gooderham, S. Kalia, 2017, Journal of cutaneous medicine and surgery.

Integrating Biologic Agents into Management of Moderate-to-Severe Psoriasis: A Consensus of the Canadian Psoriasis Expert Panel

K. Papp, R. Bissonnette, Y. Poulin, 2004, Journal of cutaneous medicine and surgery.

Efficacy and safety of topical WBI‐1001 in patients with mild to severe atopic dermatitis: results from a 12‐week, multicentre, randomized, placebo‐controlled double‐blind trial

R. Bissonnette, Y. Poulin, Y. Zhou, 2012, The British journal of dermatology.

Adalimumab for nail psoriasis: efficacy and safety over 52 weeks from a phase‐3, randomized, placebo‐controlled trial

Y. Poulin, B. Elewski, M. Okun, 2019, Journal of the European Academy of Dermatology and Venereology : JEADV.

Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo‐controlled trial

B. Elewski, K. Papp, Y. Poulin, 2018, Journal of the American Academy of Dermatology.

Ustekinumab improves nail disease in patients with moderate‐to‐severe psoriasis: results from PHOENIX 1

Y. Wasfi, Y. Poulin, S. Fakharzadeh, 2014, The British journal of dermatology.

Australasian College of Dermatologists Abstracts Presented at the 52nd Annual Scientific Meeting 18–21 May 2019 Melbourne Convention and Exhibition Centre Melbourne, Victoria

M. Lebwohl, K. Khosrotehrani, A. Verma, 2019, Australasian Journal of Dermatology.

Prevalence and Epidemiology of Onychomycosis

Y. Poulin, C. Lynde, R. Vender, 2006 .

Efficacy and safety of follow‐up field treatment of actinic keratosis with ingenol mebutate 0·015% gel: a randomized, controlled 12‐month study

C. Garbe, J. Lear, N. Basset-Seguin, 2016, British Journal of Dermatology.

A Phase 2 Randomized Trial of Apremilast in Patients with Atopic Dermatitis.

E. Simpson, M. Suárez-Fariñas, H. Wen, 2019, The Journal of investigative dermatology.

Update on Alefacept Safety

W. Gulliver, K. Papp, R. Bissonnette, 2009, Journal of cutaneous medicine and surgery.

XP-828 L in the Treatment of Mild-to-Moderate Psoriasis : A Randomized , Double-blind , Placebo-controlled Study

R. Bissonnette, Y. Poulin, P. Poubelle, 2007 .

XP-828L in the Treatment of Mild to Moderate Psoriasis: Randomized, Double-Blind, Placebo-Controlled Study

R. Bissonnette, Y. Poulin, P. Poubelle, 2006, Journal of cutaneous medicine and surgery.

Recommendations for incorporating biologicals into management of moderate to severe plaque psoriasis: individualized patient approaches

K. Papp, Y. Poulin, N. Shear, 2005, Journal of cutaneous medicine and surgery.

Incorporating Biologics into the Treatment of Psoriasis

H. Lui, W. Gulliver, Y. Poulin, 2004, Journal of cutaneous medicine and surgery.

Preface: Psoriasis Today—A New Paradigm

Y. Poulin, 2004 .

The Use of Alefacept in the Treatment of Psoriasis

W. Gulliver, Y. Poulin, L. Guenther, 2004, Journal of cutaneous medicine and surgery.

Incorporating Biologics into the Treatment of Psoriasis

H. Lui, W. Gulliver, Y. Poulin, 2004, Journal of cutaneous medicine and surgery.

The Use of Alefacept in the Treatment of Psoriasis

W. Gulliver, Y. Poulin, L. Guenther, 2004, Journal of Cutaneous Medicine and Surgery.

Preface: Psoriasis Today—A New Paradigm

Y. Poulin, 2004 .

Safety and Efficacy of Pimecrolimus in Atopic Dermatitis: A 5-Year Randomized Trial

J. Ring, A. Paller, T. Luger, 2015, Pediatrics.

Topical treatment of actinic keratoses with 3·0% diclofenac in 2·5% hyaluronan gel

Y. Poulin, L. Guenther, N. Shear, 2002, The British journal of dermatology.

Assessment of the long-term safety and effectiveness of etanercept for the treatment of psoriasis in an adult population.

K. Papp, R. Bissonnette, Y. Poulin, 2012, Journal of the American Academy of Dermatology.

Canadian Clinical Practice Guidelines for Rosacea

C. Cochrane, A. Baibergenova, Y. Poulin, 2016, Journal of cutaneous medicine and surgery.

Use of Systemic Therapies for Treatment of Psoriasis in People Living with Controlled HIV: Inference-Based Guidance from a Multidisciplinary Expert Panel

S. Walmsley, M. Gooderham, K. Papp, 2022, Dermatology and Therapy.

Facial Lipoatrophy following Systemic Lupus Erythematosus

Y. Poulin, A. Dupéré, 2003 .

Facial Lipoatrophy Following Systemic Lupus Erythematosus

Y. Poulin, A. Dupéré, 2003, Journal of cutaneous medicine and surgery.

Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double‐blinded, placebo‐controlled studies (CIMPASI‐1 and CIMPASI‐2)

A. Gottlieb, K. Reich, A. Blauvelt, 2018, Journal of the American Academy of Dermatology.

Management of acne: Canadian clinical practice guideline

A. Baibergenova, Y. Poulin, Jerry Tan, 2016, Canadian Medical Association Journal.

Long-term Management of Moderate to Severe Plaque Psoriasis Patients With Etanercept

W. Gulliver, K. Papp, Y. Poulin, 2015, Journal of cutaneous medicine and surgery.

A Canadian Self-Administered Online Survey to Evaluate the Impact of Moderate-to-Severe Psoriasis among Patients

K. Papp, Y. Poulin, N. Wasel, 2009, Journal of cutaneous medicine and surgery.

Impact of ustekinumab on health‐related quality of life and sexual difficulties associated with psoriasis: results from two phase III clinical trials

C. Han, Y. Poulin, L. Guenther, 2011, Journal of the European Academy of Dermatology and Venereology : JEADV.

The Burden of Psoriasis in Canada: Insights from the pSoriasis Knowledge IN Canada (SKIN) Survey

C. Jackson, Y. Poulin, L. Guenther, 2009, Journal of cutaneous medicine and surgery.

Efficacy of tildrakizumab by patient demographic and disease characteristics across a phase 2b and 2 phase 3 trials in patients with moderate‐to‐severe chronic plaque psoriasis

Y. Poulin, A. Mendelsohn, S. Rozzo, 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.

Long‐term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate‐to‐severe psoriasis: results from the PHOENIX 2 study through 5 years of follow‐up

M. Lebwohl, K. Reich, Y. Wasfi, 2015, The British journal of dermatology.

A comparison of tazarotene 0.1% gel once daily plus mometasone furoate 0.1% cream once daily versus calcipotriene 0.005% ointment twice daily in the treatment of plaque psoriasis.

Y. Poulin, L. Guenther, D. Pariser, 2000, Clinical therapeutics.

A Canadian online survey to evaluate awareness and treatment satisfaction in individuals with moderate to severe plaque psoriasis

K. Papp, Y. Poulin, N. Wasel, 2010, International journal of dermatology.

Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: results from an open-label extension study for patients from REVEAL.

E. Sasso, K. Papp, K. Gordon, 2012, Journal of the American Academy of Dermatology.

Interleukin 17A: toward a new understanding of psoriasis pathogenesis.

Y. Poulin, C. Lynde, R. Vender, 2014, Journal of the American Academy of Dermatology.

Serious infections in patients with self-reported psoriatic arthritis from the Psoriasis Longitudinal Assessment and Registry (PSOLAR) treated with biologics

A. Gottlieb, C. Ritchlin, Y. Poulin, 2019, BMC Rheumatology.

Think beyond the Skin

W. Gulliver, Y. Poulin, C. Lynde, 2015, Journal of cutaneous medicine and surgery.

Management of Plaque Psoriasis With Biologic Therapies in Women of Child-Bearing Potential Consensus Paper

M. Gooderham, K. Papp, Y. Poulin, 2020, Journal of cutaneous medicine and surgery.

Switching to adalimumab for psoriasis patients with a suboptimal response to etanercept, methotrexate, or phototherapy: efficacy and safety results from an open-label study.

B. Strober, K. Papp, F. Kerdel, 2011, Journal of the American Academy of Dermatology.

Changes in C‐reactive protein in patients with moderate‐to‐severe psoriasis switched to adalimumab therapy after suboptimal response to etanercept, methotrexate or phototherapy

B. Strober, Y. Poulin, D. Williams, 2014, Journal of the European Academy of Dermatology and Venereology : JEADV.

Feasibility and Utility of the Psoriasis Symptom Inventory (PSI) in Clinical Care Settings: A Study from the International Psoriasis Council

B. Strober, J. M. van der Walt, P. C. van de Kerkhof, 2019, American Journal of Clinical Dermatology.

Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)*

K. Peris, M. Cork, M. Worm, 2020, The British journal of dermatology.

Efficacy of Etanercept in the Management of Plaque Psoriasis and Psoriatic Arthritis

Y. Poulin, Aditya K. Gupta, J. Amiss, 2007 .

A randomized study comparing the combination of nbUVB and etanercept to etanercept monotherapy in patients with psoriasis who do not exhibit an excellent response after 12 weeks of etanercept

R. Bissonnette, Y. Poulin, L. Guenther, 2012, The Journal of dermatological treatment.

Long‐term outcomes of interruption and retreatment vs. continuous therapy with adalimumab for psoriasis: subanalysis of REVEAL and the open‐label extension study

E. Sasso, A. Menter, Y. Poulin, 2013, Journal of the European Academy of Dermatology and Venereology : JEADV.

Apremilast for the treatment of moderate‐to‐severe palmoplantar psoriasis: results from a double‐blind, placebo‐controlled, randomized study

M. Gooderham, J. Fowler, R. Bissonnette, 2018, Journal of the European Academy of Dermatology and Venereology : JEADV.

Canadian Guidelines for the Management of Plaque Psoriasis: Overview

J. Ashkenas, W. Gulliver, K. Papp, 2011, Journal of cutaneous medicine and surgery.

Treatment of palmoplantar psoriasis with infliximab: a randomized, double‐blind placebo‐controlled study

R. Bissonnette, Y. Poulin, L. Guenther, 2011, Journal of the European Academy of Dermatology and Venereology : JEADV.

Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate‐to‐severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2)

G. Girolomoni, M. Gooderham, U. Mrowietz, 2015, The British journal of dermatology.

Successful Treatment of Hidradenitis Suppurativa with Infliximab in a Patient Who Failed to Respond to Etanercept

Y. Poulin, 2009, Journal of cutaneous medicine and surgery.

Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis

D. Shrom, R. Burge, M. Ohtsuki, 2017, Journal of the European Academy of Dermatology and Venereology : JEADV.

Calcium Analysis by Continuous Flow and Atomic Absorption Spectrophotometry Compared

C. Fisch, D. Shapcott, Y. Poulin, 2004 .

Approach to the Assessment and Management of Adult Patients With Atopic Dermatitis: A Consensus Document. Section IV: Treatment Options for the Management of Atopic Dermatitis

M. Gooderham, R. Gniadecki, Y. Poulin, 2018, Journal of cutaneous medicine and surgery.

Practical Approach to the Hormonal Treatment of Acne

Y. Poulin, 2005, Journal of cutaneous medicine and surgery.

Pemphigus vulgaris: results of treatment with gold as a steroid-sparing agent in a series of thirteen patients.

Y. Poulin, S. Muller, H. Perry, 1984, Journal of the American Academy of Dermatology.

Checklist for the Systemic Treatment of Psoriasis Using Biologics: A Delphi Study

W. Gulliver, M. Gooderham, C. Fahim, 2019, Journal of cutaneous medicine and surgery.

Impact of ixekizumab treatment on skin‐related personal relationship difficulties in moderate‐to‐severe psoriasis patients: 12‐week results from two Phase 3 trials

M. Lebwohl, K. Reich, R. Warren, 2017, Journal of the European Academy of Dermatology and Venereology : JEADV.

An Open Letter to Health Canada

W. Gulliver, M. Wiseman, M. Gooderham, 2017, Journal of cutaneous medicine and surgery.

Immune response to pneumococcus and tetanus toxoid in patients with moderate-to-severe psoriasis following long-term ustekinumab use.

K. Papp, Y. Poulin, L. Guenther, 2013, Journal of drugs in dermatology : JDD.

Calcipotriol and betamethasone dipropionate (Dovobet, Daivobet): a new formulation for the treatment of psoriasis.

Y. Poulin, 2002, Skin therapy letter.

Phase 2b Randomized Study of Nemolizumab in Adults with Moderate-Severe Atopic Dermatitis and Severe Pruritus.

J. Silverberg, A. Wollenberg, D. Murrell, 2019, The Journal of allergy and clinical immunology.

Disease activity and treatment efficacy using patient-level Psoriasis Area and Severity Index scores from tildrakizumab phase 3 clinical trials

K. Reich, K. Gordon, Y. Poulin, 2020, The Journal of dermatological treatment.

A Treatment Algorithm for Moderate to Severe Atopic Dermatitis in Adults

M. Gooderham, K. Papp, Y. Poulin, 2018, Journal of cutaneous medicine and surgery.

Development and Validation of a Comprehensive Acne Severity Scale

W. Gulliver, Y. Poulin, Jerry Tan, 2007, Journal of cutaneous medicine and surgery.

Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis.

J. Silverberg, Y. Soo, T. Bieber, 2016, The New England journal of medicine.

A randomized, multicenter, double-blind, placebo-controlled phase 2 trial of ISA247 in patients with chronic plaque psoriasis.

K. Papp, R. Bissonnette, Y. Poulin, 2006, Journal of the American Academy of Dermatology.

The Relationship Between Dermatologist- and Patient-Reported Acne Severity Measures and Treatment Recommendations

W. Gulliver, M. Frey, Y. Poulin, 2015, Journal of cutaneous medicine and surgery.

The efficacy of adapalene-benzoyl peroxide combination increases with number of acne lesions.

S. Feldman, Y. Poulin, Jerry Tan, 2011, Journal of the American Academy of Dermatology.

Development and Validation of a Scale for Acne Scar Severity (SCAR-S) of the Face and Trunk

W. Gulliver, Y. Poulin, Jerry Tan, 2010, Journal of cutaneous medicine and surgery.

Non-melanoma Skin Cancer in Canada Chapter 3: Management of Actinic Keratoses

J. Ashkenas, Y. Poulin, C. Lynde, 2015, Journal of cutaneous medicine and surgery.

Efficacy of Secukinumab in the Treatment of Moderate to Severe Plaque Psoriasis in the North American Subgroup of Patients: Pooled Analysis of Four Phase 3 Studies

J. Schlessinger, Y. Poulin, R. Langley, 2017, Dermatology and Therapy.

Non-melanoma Skin Cancer in Canada Chapter 5: Management of Squamous Cell Carcinoma

J. Ashkenas, Y. Poulin, P. Janiszewski, 2015, Journal of cutaneous medicine and surgery.

Practical Aspects of Prescribing a Biologic

Y. Poulin, M. Bourcier, 2009, Journal of cutaneous medicine and surgery.

Management of chronic spontaneous urticaria (CSU): a treat to target approach using a patient reported outcome

M. Gooderham, K. Papp, Y. Poulin, 2017, Allergy, Asthma & Clinical Immunology.

TYK2/JAK1 Inhibitor PF-06700841 in Patients with Plaque Psoriasis: Phase IIa, Randomized, Double-blind, Placebo-controlled Trial.

E. Peeva, S. Forman, Y. Poulin, 2020, The Journal of investigative dermatology.

Biologics in the Treatment of Psoriasis: Clinical and Economic Overview

Y. Poulin, R. Langley, H. Teixeira, 2009, Journal of cutaneous medicine and surgery.

North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part I: Diagnosis, evaluation, and the use of complementary and procedural management.

A. Gottlieb, A. Kimball, Karen E Crowell, 2019, Journal of the American Academy of Dermatology.

Cost‐effectiveness evaluation of clobetasol propionate shampoo (CPS) maintenance in patients with moderate scalp psoriasis: a Pan‐European analysis

K. Papp, Y. Poulin, N. Kerrouche, 2012, Journal of the European Academy of Dermatology and Venereology : JEADV.

Calciphylaxis: Seven New Cases

Y. Poulin, É. Gagné, Jimmy Alain, 2000, Journal of cutaneous medicine and surgery.

A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: a randomized, double-blind, controlled trial.

J. Ortonne, B. Berne, G. Jemec, 2008, Journal of the American Academy of Dermatology.

A new calcipotriol/betamethasone formulation with rapid onset of action was superior to monotherapy with betamethasone dipropionate or calcipotriol in psoriasis vulgaris.

J. Ortonne, F. G. Larsen, W. Gulliver, 2002, Acta dermato-venereologica.

Brief Treatment Guide for Onychomycosis

Y. Poulin, Yves Poulin, Richard Thomas, 2006 .

Canadian Perspectives on Antifungal Treatment for Onychomycosis

Y. Poulin, C. Lynde, Aditya K. Gupta, 2006 .

Pyodermatitis—Pyostomatitis Vegetans: Two Cases and a Review of the Literature

Y. Poulin, S. Nigen, É. Gagné, 2003 .

Pyodermatitis–Pyostomatitis Vegetans: Two Cases and a Review of the Literature

Y. Poulin, S. Nigen, É. Gagné, 2003, Journal of cutaneous medicine and surgery.

Olmsted Syndrome—Palmoplantar and Periorificial Keratodermas: Association with Malignant Melanoma

Y. Poulin, M. Bourcier, É. Gagné, 2003, Journal of cutaneous medicine and surgery.

Olmsted syndrome--congenital palmoplantar and periorificial keratoderma.

Y. Poulin, S. Muller, H. Perry, 1984, Journal of the American Academy of Dermatology.

Clobetasol propionate shampoo 0.05% is efficacious and safe for long-term control of moderate scalp psoriasis

K. Papp, R. Bissonnette, Y. Poulin, 2010, The Journal of dermatological treatment.

Clobetasol propionate shampoo 0.05%: a new option to treat patients with moderate to severe scalp psoriasis.

A. Gottlieb, Y. Poulin, Yin Liu, 2004, Journal of drugs in dermatology : JDD.

Off-Label Use of Topical Calcineurin Inhibitors in Dermatologic Disorders

Y. Poulin, L. Guenther, C. Lynde, 2019, Journal of cutaneous medicine and surgery.

Clobetasol propionate shampoo 0.05% is efficacious and safe for long-term control of scalp psoriasis.

K. Papp, R. Bissonnette, Y. Poulin, 2010, Cutis.

Efficacy of adalimumab across subgroups of patients with moderate-to-severe chronic plaque psoriasis of the hands and/or feet: post hoc analysis of REACH

Y. Poulin, R. Langley, R. Langley, 2013, Journal of the European Academy of Dermatology and Venereology : JEADV.

Olmsted Syndrome—Palmoplantar and Periorificial Keratodermas: Association with Malignant Melanoma

Y. Poulin, M. Bourcier, É. Gagné, 2003 .

A Review of the Efficacy and Safety for Biologic Agents Targeting IL-23 in Treating Psoriasis With the Focus on Tildrakizumab

M. Wiseman, Y. Poulin, C. Lynde, 2021, Frontiers in Medicine.

Onset of pruritus relief with pimecrolimus cream 1% in adult patients with atopic dermatitis: a randomized trial

B. L. Andersen, T. Bieber, T. Luger, 2006, Allergy.

Canadian Hand Dermatitis Management Guidelines

T. Agner, W. Gulliver, R. Bissonnette, 2010, Journal of cutaneous medicine and surgery.

North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part II: Topical, intralesional, and systemic medical management.

A. Gottlieb, A. Kimball, Karen E Crowell, 2019, Journal of the American Academy of Dermatology.

Risk of Serious Infection With Biologic and Systemic Treatment of Psoriasis: Results From the Psoriasis Longitudinal Assessment and Registry (PSOLAR).

M. Lebwohl, Y. You, C. Leonardi, 2015, JAMA dermatology.

Two randomized studies demonstrate the efficacy and safety of dapsone gel, 5% for the treatment of acne vulgaris.

B. Elewski, E. Carter, Z. Draelos, 2007, Journal of the American Academy of Dermatology.

Gene expression profiling in psoriatic scalp hair follicles: clobetasol propionate shampoo 0.05% normalizes psoriasis disease markers

H. Lui, J. Shapiro, Y. Poulin, 2010, Journal of the European Academy of Dermatology and Venereology : JEADV.

Adapalene gel 0.3% for the treatment of acne vulgaris: a multicenter, randomized, double-blind, controlled, phase III trial.

J. Herndon, Y. Poulin, D. Thiboutot, 2006, Journal of the American Academy of Dermatology.

Tazarotene 0.1% cream versus tretinoin 0.05% emollient cream in the treatment of photodamaged facial skin: a multicenter, double‐blind, randomized, parallel‐group study

Sewon Kang, Y. Poulin, Y. Tse, 2004 .

Strategies for optimizing treatment with efalizumab in moderate to severe psoriasis

K. Papp, Y. Poulin, N. Shear, 2005, Journal of cutaneous medicine and surgery.

Disease characteristics in patients with and without psoriatic arthritis treated with etanercept

K. Papp, Y. Poulin, K. Papp, 2014, Journal of the European Academy of Dermatology and Venereology : JEADV.

Efficacy and safety of adalimumab in patients with plaque psoriasis who have shown an unsatisfactory response to etanercept.

R. Bissonnette, Y. Poulin, L. Guenther, 2010, Journal of the American Academy of Dermatology.

Real-World Experience With Apremilast in the Treatment of Adults With Moderate to Severe Plaque Psoriasis in Québec: A Claims-Based Analysis of Drug Utilization and Healthcare Resource Utilization

C. Beauchemin, Y. Poulin, J. Lachaine, 2020, Journal of cutaneous medicine and surgery.

Apremilast, an oral phosphodiesterase 4 inhibitor, improves patient‐reported outcomes in the treatment of moderate to severe psoriasis: results of two phase III randomized, controlled trials

S. Feldman, A. Kimball, P. Foley, 2016, Journal of the European Academy of Dermatology and Venereology : JEADV.

Position statement for a pragmatic approach to immunotherapeutics in patients with inflammatory skin diseases during the coronavirus disease 2019 pandemic and beyond

P. Gisondi, M. Gooderham, R. Gniadecki, 2021, Journal of the European Academy of Dermatology and Venereology : JEADV.

Cultural and linguistic validation of acne‐QoL in French

B. Dréno, Y. Poulin, J. Tan, 2012, Journal of the European Academy of Dermatology and Venereology : JEADV.

Divergence of Demographic Factors Associated with Clinical Severity Compared with Quality of Life Impact in Acne

W. Gulliver, Y. Poulin, Jerry Tan, 2008, Journal of cutaneous medicine and surgery.

Management of Moderate to Severe Plaque Psoriasis: The Emerging Role of IL-17 Inhibition

M. Wiseman, M. Gooderham, K. Papp, 2017, Journal of cutaneous medicine and surgery.

Psychometric properties of the French Female Sexual Function Index (FSFI)

R. Rouzier, B. Dréno, M. Hanf, 2014, Quality of Life Research.

Evidence that a neutrophil–keratinocyte crosstalk is an early target of IL-17A inhibition in psoriasis

Martin M. Schumacher, F. Kolbinger, K. Papp, 2015, Experimental dermatology.

Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial

M. Gooderham, K. Papp, R. Bissonnette, 2016, The British journal of dermatology.

Impact of ixekizumab on facial psoriasis and related quality of life measures in moderate‐to‐severe psoriasis patients: 12‐week results from two phase III trials

Y. Poulin, L. Guenther, C. Paul, 2018, Journal of the European Academy of Dermatology and Venereology : JEADV.

Ixekizumab Results in Persistent Clinical Improvement in Moderateto-Severe Genital Psoriasis During a 52 Week, Randomized, Placebo-Controlled, Phase 3 Clinical Trial

J. Erickson, R. Burge, C. Ryan, 2020, Acta dermato-venereologica.

Y. Poulin, Yihua Gu, H. Teixeira, 2014, Dermatology and Therapy.

Analysis of body regions and components of PASI scores during adalimumab or methotrexate treatment for patients with moderate-to-severe psoriasis.

A. Menter, A. Navarini, Y. Poulin, 2014, Journal of drugs in dermatology : JDD.

Efficacy and safety of risankizumab vs. secukinumab in patients with moderate‐to‐severe plaque psoriasis (IMMerge): results from a phase III, randomized, open‐label, efficacy–assessor‐blinded clinical trial*

T. Wu, A. Blauvelt, R. Warren, 2020, The British journal of dermatology.

Review of Systemic Treatment Options for Adult Atopic Dermatitis

W. Gulliver, M. Gooderham, K. Papp, 2017, Journal of cutaneous medicine and surgery.

A multicenter, double-blind, randomized comparison study of the efficacy and tolerability of once-daily tazarotene 0.1% gel and adapalene 0.1% gel for the treatment of facial acne vulgaris.

Y. Poulin, L. Guenther, G. Webster, 2002, Cutis.

B. Hales, Y. Poulin, N. Shear, 2009, Journal of cutaneous medicine and surgery.

The Use of Alefacept in the Treatment of Psoriasis

W. Gulliver, Y. Poulin, L. Guenther, 2004, Journal of cutaneous medicine and surgery.

Examining the Risk of Cardiovascular Disease in Patients with Psoriasis: A Critical Review

K. Papp, Y. Poulin, A. Vieira, 2013, Journal of cutaneous medicine and surgery.

Drug-Induced Hepatitis and Lupus during Infliximab Treatment for Psoriasis: Case Report and Literature Review

Y. Poulin, Geneviàve Thérien, Geneviève Thérien, 2010, Journal of cutaneous medicine and surgery.

Treating Psoriasis and Psoriatic Arthritis: Position Paper on Applying the Treat-to-target Concept to Canadian Daily Practice

D. Gladman, P. Rahman, J. Karsh, 2017, The Journal of Rheumatology.

Oral contraceptives as anti-androgenic treatment of acne.

Y. Poulin, A. Lemay, 2002, Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC.

Treatment of Acne Vulgaris and Prevention of Acne Scarring: Canadian Consensus Guidelines

Kevin C. Smith, H. Degreef, Y. Poulin, 2000, Journal of cutaneous medicine and surgery.

Prevalence and severity of facial and truncal acne in a referral cohort.

W. Gulliver, Y. Poulin, Jerry Tan, 2008, Journal of drugs in dermatology : JDD.

A 6‐month maintenance therapy with adapalene‐benzoyl peroxide gel prevents relapse and continuously improves efficacy among patients with severe acne vulgaris: results of a randomized controlled trial

J. Fowler, Y. Poulin, N. Kerrouche, 2011, The British journal of dermatology.

Long‐term efficacy of certolizumab pegol for the treatment of plaque psoriasis: 3‐year results from two randomized phase III trials (CIMPASI‐1 and CIMPASI‐2)

A. Gottlieb, K. Reich, K. Gordon, 2020, The British journal of dermatology.

Evaluating practice patterns for managing moderate to severe plaque psoriasis: role of the family physician.

K. Papp, Y. Poulin, N. Wasel, 2012, Canadian family physician Medecin de famille canadien.

Epidemiology of Moderate-to-Severe Plaque Psoriasis in a Canadian Surveyed Population

K. Papp, Y. Poulin, F. Valenzuela, 2010, Journal of cutaneous medicine and surgery.

Psoriasis Prevalence and Severity by Expert Elicitation

M. Gooderham, K. Papp, R. Gniadecki, 2021, Dermatology and Therapy.

Pathogenesis of Psoriasis and Current Challenges

H. Lui, Y. Poulin, R. Langley, 2004, Journal of cutaneous medicine and surgery.

2016 Addendum to the Canadian Guidelines for the Management of Plaque Psoriasis 2009

W. Gulliver, M. Wiseman, M. Gooderham, 2016 .

Tazarotene in combination with topical corticosteroids.

M. Lebwohl, Y. Poulin, 1998, Journal of the American Academy of Dermatology.

Efficacy of Imiquimod as an Adjunct to Cryotherapy for Actinic Keratoses

Y. Poulin, Jerry Tan, D. R. Thomas, 2007, Journal of cutaneous medicine and surgery.

Nail Outcome Improvements with Certolizumab Pegol in Moderate to Severe Plaque Psoriasis: Results from Phase 3 Trials

A. Gottlieb, K. Reich, Y. Poulin, 2019, SKIN The Journal of Cutaneous Medicine.

Approach to the Assessment and Management of Adult Patients With Atopic Dermatitis: A Consensus Document

M. Wiseman, M. Gooderham, K. Papp, 2018, Journal of Cutaneous Medicine and Surgery.

A North American study of adapalene-benzoyl peroxide combination gel in the treatment of acne.

J. Schlessinger, K. Papp, Y. Poulin, 2009, Cutis.

Effect of Quality of Life Impact and Clinical Severity on Adherence to Topical Acne Treatment

W. Gulliver, Y. Poulin, Jerry Tan, 2009, Journal of cutaneous medicine and surgery.

Randomized Placebo-Controlled Trial of Metronidazole 1 % Cream with Sunscreen SPF 15 in Treatment of Rosacea

K. Papp, Y. Poulin, A. Krol, 2002 .

Randomized Placebo-controlled Trial of Metronidazole 1% Cream with Sunscreen SPF 15 in Treatment of Rosacea

K. Papp, Y. Poulin, A. Krol, 2002, Journal of cutaneous medicine and surgery.

OBSERVE-5: Comparison of Etanercept-Treated Psoriasis Patients From Canada and the United States

K. Papp, Y. Poulin, C. Lynde, 2018, Journal of cutaneous medicine and surgery.

Etanercept in the treatment of palmoplantar pustulosis.

R. Bissonnette, Y. Poulin, J. Syrotuik, 2008, Journal of drugs in dermatology : JDD.

Improvements in patient‐reported outcomes in patients with psoriasis receiving etanercept plus topical therapies: results from REFINE

R. Bissonnette, Y. Poulin, C. Lynde, 2015, Journal of the European Academy of Dermatology and Venereology : JEADV.

A Randomized, blinded assessor study to Evaluate the efFIcacy and safety of etanercept 50 mg once weekly plus as Needed topical agent vs. Etanercept 50 mg twice weekly in patients with moderate to severe plaque psoriasis (REFINE)

R. Bissonnette, Y. Poulin, K. Papp, 2014, Journal of the European Academy of Dermatology and Venereology : JEADV.

A favourable benefit/risk ratio with efalizumab: A review of the clinical evidence

W. Gulliver, K. Papp, Y. Poulin, 2005, Journal of cutaneous medicine and surgery.

Practical and Relevant Guidelines for the Management of Psoriasis: An Inference-Based Methodology

M. Gooderham, K. Papp, R. Gniadecki, 2021, Dermatology and Therapy.

Safety and Efficacy of a Milk-Derived Extract in the Treatment of Plaque Psoriasis: An Open-Label Study

Y. Poulin, S. Gauthier, Y. Pouliot, 2005 .

Safety and Efficacy of a Milk-derived Extract in the Treatment of Plaque Psoriasis:An Open-label Study

Y. Poulin, S. Gauthier, Y. Pouliot, 2005, Journal of cutaneous medicine and surgery.

Early relapse of psoriasis after stopping brodalumab: a retrospective cohort study in 77 patients

Y. Poulin, C. Livideanu, C. Paul, 2017, Journal of the European Academy of Dermatology and Venereology : JEADV.

Treatment Guidelines for Atopic Dermatitis Since the Approval of Dupilumab: A Systematic Review and Quality Appraisal Using AGREE-II

V. Piguet, S. Kalia, Y. Poulin, 2022, Frontiers in Medicine.

Reduced Risk of Mortality Associated With Systemic Psoriasis Treatment in the Psoriasis Longitudinal Assessment and Registry (PSOLAR): A Nested Case-Control Analysis.

M. Augustin, Y. Poulin, R. Langley, 2020, Journal of the American Academy of Dermatology.

Canadian Clinical Practice Guidelines for Rosacea

C. Cochrane, A. Baibergenova, Y. Poulin, 2016, Journal of cutaneous medicine and surgery.

Approach to the Assessment and Management of Adult Patients With Atopic Dermatitis: A Consensus Document. Section V: Consensus Statements on the Assessment and Management of Adult Patients With Moderate-to-Severe Atopic Dermatitis

M. Wiseman, M. Gooderham, K. Papp, 2018, Journal of cutaneous medicine and surgery.

Management of Moderate to Severe Plaque Psoriasis: The Emerging Role of IL-17 Inhibition

M. Wiseman, M. Gooderham, K. Papp, 2017, Journal of cutaneous medicine and surgery.

Long‐term outcomes of interruption and retreatment vs. continuous therapy with adalimumab for psoriasis: subanalysis of REVEAL and the open‐label extension study

Y. Poulin, Alan Menter, Kim Papp, 2013, Journal of the European Academy of Dermatology and Venereology : JEADV.

Canadian Guidelines for the Management of Plaque Psoriasis: Overview

J. Ashkenas, W. Gulliver, K. Papp, 2011, Journal of cutaneous medicine and surgery.

Efficacy and Safety of Pimecrolimus Cream 1% in Mild-to-Moderate Chronic Hand Dermatitis: A Randomized, Double-Blind Trial

A. Fleischer, Y. Poulin, J. Rivers, 2010, Dermatology.